ALX Oncology Holdings (NASDAQ:ALXO) presented its Q2 2025 results on August 12, 2025, highlighting its focused development strategy around evorpacept, a CD47-targeting immunotherapy, and ALX2004, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results